Blood ; Supplement 1 : Objective There are many kinds of prognostic scoring systems of myelodysplastic syndrome MDS which are all risk-based stratification systems with their own dominance. So we do this research to explore the significance among this three systems in predicting the prognosis of MDS and to guide the clinical accurate prognosis stratification for personal treatment. Then we compare the fatality rate of different stratifications in each system from the 0th month to the 60th month and contrast the 2-year fatality rate of each stratification.

Author:Gomuro Vukus
Language:English (Spanish)
Published (Last):6 April 2014
PDF File Size:10.43 Mb
ePub File Size:10.50 Mb
Price:Free* [*Free Regsitration Required]

Approximately one-third of patients with myelodysplastic syndrome MDS receiving allogeneic hematopoietic stem cell transplantation HSCT are cured by this treatment. Treatment failure may be due to transplant complications or relapse. Univariate and multivariate survival analyses were performed using Cox proportional hazards regression.

High-risk category, as defined by the revised International Prognostic Scoring System IPSS-R , and monosomal karyotype were independently associated with relapse and lower overall survival after transplantation. On the other hand, older recipient age and high hematopoietic cell transplantation-comorbidity index HCT-CI were independent predictors of nonrelapse mortality.

In addition, it reinforces the concept that allogeneic HSCT offers optimal eradication of myelodysplastic hematopoiesis when the procedure is performed before MDS patients progress to advanced disease stages. This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Clipboard, Search History, and several other advanced features are temporarily unavailable. Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text. Send email Cancel. Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters.

Choose a collection: Unable to load your collection due to an error Please try again. Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items.

Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel. Full-text links Cite Favorites. Abstract Approximately one-third of patients with myelodysplastic syndrome MDS receiving allogeneic hematopoietic stem cell transplantation HSCT are cured by this treatment.

Yang YT, et al. Am J Hematol. Epub Jun PMID: Alzahrani M, et al. Biol Blood Marrow Transplant. Epub Feb Gauthier J, et al. Diagnosis and therapeutic strategies]. Aul C, et al. Med Klin Munich. PMID: Review. The evolution of hematopoietic SCT in myelodysplastic syndrome. Kindwall-Keller T, et al. Bone Marrow Transplant. Epub Mar 2. Show more similar articles See all similar articles. Henriques D, et al. Front Neurosci.

A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes. Gooptu M, Koreth J. Gooptu M, et al. No abstract available. Narayan R, et al. Epub Apr 3.

Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation. Ishiyama K, et al.

Blood Cancer J. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Gagelmann N, et al. Epub Jan Show more "Cited by" articles See all "Cited by" articles. Publication types Research Support, Non-U. Gov't Actions. MeSH terms Adolescent Actions. Adult Actions. Aged Actions. Allografts Actions. Female Actions. Humans Actions. Kaplan-Meier Estimate Actions.

Male Actions. Middle Aged Actions. Prognosis Actions. Proportional Hazards Models Actions. Recurrence Actions. Risk Factors Actions. Treatment Outcome Actions. Young Adult Actions. Full-text links [x] Silverchair Information Systems. Copy Download.


[International prostate symptom score: comparison of doctor and patient].

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page. Disabil Rehabil , , 29 Jan Cited by 1 article PMID: Clin Transl Oncol , 15 8 , 29 Jan Cited by 3 articles PMID:


Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. The American Urological association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol.



Related Articles